MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

27 Oct 2022 Evaluate

Alembic Pharmaceuticals has informed the exchange that the company has received US Food & Drug Administration (USFDA) Final Approval for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) Multiple-Dose Vials. The company has enclosed a press release in this regard.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..